The firm's operating loss widened to $46.1 million in 2026Q1, reflecting a cost structure dominated by clinical obligations rather than scalable revenue generation.
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 0 | 0 | 0 | 0 | 0 |
| COGS % of Revenue | - | - | - | - | - | - |
| Gross Profit | 0 | 0 | 0 | 0 | 0 | 0 |
| Gross Margin % | - | - | - | - | - | - |
| Gross Profit Growth % | - | - | - | - | - | - |
| Operating Expenses | 156.87M | 177.53M | 94.31M | 74.59M | 36.91M | 8.7M |
| OpEx % of Revenue | - | - | - | - | - | - |
| Selling, General & Admin | 27.19M | 24.18M | 15.3M | 9.71M | 6.47M | 2.26M |
| SG&A % of Revenue | - | - | - | - | - | - |
| Research & Development | 129.68M | 153.35M | 79M | 64.88M | 30.43M | 6.43M |
| R&D % of Revenue | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -156.87M | -177.53M | -94.31M | -74.59M | -36.91M | -8.7M |
| Operating Margin % | - | - | - | - | - | - |
| Operating Income Growth % | - | -88.25% | -26.44% | -102.11% | -324.4% | - |
| EBITDA | -151.31M | -177.53M | -80.49M | -74.59M | 0 | -51.61M |
| EBITDA Margin % | - | - | - | - | - | - |
| EBITDA Growth % | -7.77% | -120.57% | -7.91% | - | 100% | - |
| D&A (Non-Cash Add-back) | 0 | 0 | 0 | 0 | 36.91M | 0 |
| EBIT | -151.31M | -177.53M | -80.49M | -74.59M | -36.91M | -51.61M |
| Net Interest Income | 11.63M | 11.23M | 13.82M | 5.26M | 0 | 0 |
| Interest Income | 11.63M | 11.23M | 13.82M | 5.26M | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 11.63M | 11.23M | 13.82M | 5.26M | 0 | -42.91M |
| Pretax Income | -145.24M | -166.31M | -80.49M | -69.33M | -36.91M | -51.61M |
| Pretax Margin % | - | - | - | - | - | - |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -145.24M | -166.31M | -80.49M | -69.33M | -36.91M | -51.61M |
| Net Margin % | - | - | - | - | - | - |
| Net Income Growth % | -13.95% | -106.62% | -16.09% | -87.86% | 28.49% | - |
| Net Income (Continuing) | -145.24M | -166.31M | -80.49M | -69.33M | -36.91M | -51.61M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -3.22 | -4.32 | -2.56 | -2.17 | -1.10 | -40.44 |
| EPS Growth % | 6.37% | -68.75% | -17.97% | -97.27% | 97.28% | - |
| EPS (Basic) | - | -4.32 | -2.56 | -2.17 | -1.10 | -40.44 |
| Diluted Shares Outstanding | 45.07M | 38.46M | 31.47M | 31.96M | 33.49M | 1.28M |
| Basic Shares Outstanding | 45.07M | 38.46M | 31.47M | 31.96M | 33.49M | 1.28M |
| Dividend Payout Ratio | - | - | - | - | - | - |
Binary clinical trial failure
According to the company's recent financial disclosures, quarterly R&D spending reached a peak of $37.6 million in 2026Q1, reflecting the aggressive advancement of the FURVENT Phase 3 trial as the firm prioritizes clinical milestones over near-term expense containment.
The sharp increase in R&D investment suggests that management is prioritizing rapid enrollment to reach a potential regulatory filing. Investors should monitor whether this spending trajectory remains sustainable given the company's current cash position and the lack of offsetting commercial revenue.
As reported in the latest income statement, ArriVent's operating loss widened to $46.1 million in 2026Q1, illustrating that the company's cost structure is currently dominated by fixed clinical development obligations rather than scalable operational efficiencies.
The absence of revenue means that every dollar of SG&A and R&D directly impacts the bottom line, resulting in a lack of operating leverage. This structure appears typical for a pre-commercial biotech, yet it underscores the high sensitivity of the firm's valuation to clinical trial outcomes.
Based on the provided quarterly data, stock-based compensation has trended upward to $3.2 million in 2025Q4, which may indicate an increasing reliance on equity-based incentives to retain specialized talent during the critical late-stage development phase.
While necessary for talent retention, the rising trend in non-cash compensation warrants further investigation regarding its impact on future share dilution. Analysts should consider how these expenses affect the net loss profile and the overall cost of capital for the organization.
Financial statements indicate that the company's quarterly net loss of $43.3 million in 2026Q1 significantly outpaces its reported cash reserves, suggesting that the current capital structure may require additional financing to reach commercialization.
The reliance on external capital markets to fund ongoing operations creates a structural risk if clinical data is delayed or fails to meet primary endpoints. Investors should be wary of the potential for significant equity dilution if the company is forced to raise funds under unfavorable market conditions.
Quick answers to the most common questions about buying AVBP stock.
For fiscal year 2025, ArriVent BioPharma, Inc. Common Stock (AVBP) reported total revenue of $0.0M.
ArriVent BioPharma, Inc. Common Stock (AVBP) reported a net loss of $166.3M for the fiscal year ending 2025.